Checkpoint inhibitors and indications Anti CTLA-4 antibody: • Ipilimumab: Malignant melanoma, Renal cell cancer Anti-PD-1 antibody: • Nivolumab: Malignant melanoma, Non-small cell lung cancer, Renal cell cancer lymphoma, Head and neck cancer, Gastric cancer, Malignant mesothelioma, Colorectal cancer with high-frequency microsatellite instability (MSI-High), Esophageal cancer • Pembrolizumab: Non-small cell lung cancer, Hodgkin lymphoma, Urothelial cancer, Solid cancers with high-frequency microsatellite instability (MSI-High), Renal cell cancer, Head and neck cancer Anti PD-L1 antibody: • Atezolizumab: Non-small cell lung cancer, Small cell lung cancer, Breast cancer • Durvalumab: Non-small cell lung cancer • Avelumab: Merkel cell carcinoma renal cell cancer #Checkpoint #inhibitors #indications #oncology #pharmacology
